Emerging Therapies Using Regenerative Auditory Neurotrophin Delivery for Sensorineural Hearing Loss

Abstract

Sensorineural hearing loss (SNHL) is a prevalent and debilitating condition with limited restorative therapies. Recent advances in regenerative medicine have focused on the use of auditory neurotrophins to promote neural survival and synaptic regeneration in the cochlea. This review examines the burden of SNHL, underlying pathophysiology, clinical features, diagnostic strategies, and discusses current and emerging therapies, with a particular emphasis on neurotrophin-based interventions. Key evidence from preclinical and early clinical studies is highlighted, providing an up-to-date resource for healthcare professionals seeking to understand the translational prospects and clinical implications of neurotrophin delivery for SNHL.

Introduction

Sensorineural hearing loss affects millions globally, resulting in significant morbidity and impaired quality of life. While traditional management has relied on hearing aids and cochlear implants, these approaches do not restore native auditory function. Advances in molecular medicine have elucidated the role of neurotrophins in cochlear health and auditory nerve survival, paving the way for potential regenerative therapies. This article reviews the scientific rationale and emerging clinical applications of auditory neurotrophin delivery for SNHL.

Epidemiology / Disease Burden

SNHL is the most common type of permanent hearing loss, affecting approximately 466 million people worldwide, according to the World Health Organization. Its incidence increases with age, but it also affects neonates, children, and adults due to genetic, environmental, and idiopathic factors. The socio-economic impact is substantial, with profound implications for communication, education, and psychosocial well-being, especially in older adults who are at increased risk of cognitive decline and social isolation.

Pathophysiology

Pathologically, SNHL results from the damage or loss of sensory hair cells, spiral ganglion neurons (SGNs), or supporting cells within the cochlea. Noise exposure, ototoxic drugs, aging, and genetic mutations can lead to apoptosis or necrosis of these cells. Neurotrophins, such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), play crucial roles in cochlear development, synaptic maintenance, and neuronal survival. In SNHL, the endogenous supply of these proteins is often insufficient to prevent progressive neural degeneration, which underpins the rationale for exogenous neurotrophin delivery.

Risk Factors

Major risk factors for SNHL include aging (presbycusis), chronic noise exposure, ototoxic medications (aminoglycosides, cisplatin), hereditary mutations, viral infections (e.g., CMV), and comorbidities such as diabetes mellitus and cardiovascular disease. These factors converge on common pathways of oxidative stress, excitotoxicity, and impaired neurotrophic support, ultimately resulting in cochlear degeneration.

Clinical Features

Patients with SNHL typically present with bilateral, symmetric hearing impairment, particularly affecting high frequencies. They may report difficulty understanding speech in noisy environments, tinnitus, and in severe cases, balance disturbances. The insidious onset often delays diagnosis until functional impairment becomes significant.

Diagnosis

The diagnostic workup involves a combination of audiometric tests (pure tone audiometry, speech discrimination), otoacoustic emissions, and auditory brainstem response (ABR) measurements to localize and quantify the deficit. Imaging studies, such as MRI, may be indicated to rule out retrocochlear or central causes. Genetic testing is considered in congenital and progressive cases, and laboratory investigations may identify metabolic or infectious etiologies.

Treatment & Management

Current management strategies focus on auditory rehabilitation rather than restoration. Hearing aids amplify sound for mild to moderate loss, while cochlear implants electrically stimulate the auditory nerve in severe cases. Pharmacological interventions, such as steroids, are limited to acute inflammatory causes. Despite technological advances, these modalities do not address the underlying neurodegeneration, underscoring the need for regenerative solutions.

Recent Advances / Emerging Therapies

Regenerative approaches leveraging neurotrophin delivery have gained considerable momentum. Preclinical models demonstrate that exogenous BDNF and NT-3, delivered via viral vectors, nanoparticles, or hydrogels, can promote SGN survival and synaptic regeneration after noise or drug-induced injury. Several studies have reported successful reinnervation of inner hair cells and partial functional recovery in animal models. Early-phase clinical trials are exploring the safety and efficacy of local neurotrophin administration in cochlear implant recipients to enhance neural interface and auditory outcomes.
Gene therapy strategies aim to induce endogenous neurotrophin expression, offering sustained therapeutic effects. Coupling neurotrophin delivery with stem cell transplantation is also under investigation, with the goal of reconstructing the entire auditory circuit. However, challenges remain regarding optimal dosing, delivery routes, and long-term safety.

Guideline Recommendations

Current clinical guidelines for SNHL, such as those from the American Academy of Otolaryngology, emphasize early diagnosis, prompt rehabilitation with hearing aids or cochlear implants, and ongoing auditory training. There is growing recognition of the potential role of regenerative therapies, but neurotrophin-based treatments are not yet standard of care and remain within the research domain. Ongoing trials and registries are expected to inform future updates, with a focus on patient selection, efficacy endpoints, and safety monitoring.

Conclusion

Neurotrophin-based regenerative therapies represent a promising frontier in the management of sensorineural hearing loss. While current evidence is largely preclinical, initial human studies support the feasibility of auditory neurotrophin delivery to restore neural integrity and improve auditory outcomes. Continued research is essential to optimize delivery systems, evaluate long-term benefits, and translate these innovative therapies into clinical practice. For clinicians, awareness of these advances is critical to counseling patients and participating in future therapeutic trials that may ultimately transform the landscape of hearing loss management.